Corcept Therapeutics (CORT) Amortization of Deferred Charges (2012 - 2025)
Corcept Therapeutics (CORT) reported Amortization of Deferred Charges of $193000.0 for Q4 2025, up 7.82% on a YoY basis from $179000.0 in Q4 2024, and up 2.66% sequentially from $188000.0 in Q3 2025.
Corcept Therapeutics (CORT) Amortization of Deferred Charges (2012 - 2025) Analysis & Trends
Corcept Therapeutics (CORT) has 11 years of Amortization of Deferred Charges data on file, last reported at $193000.0 in Q4 2025.
- For the quarter ending Q4 2025, Amortization of Deferred Charges rose 7.82% year-over-year to $193000.0; the trailing twelve-month figure through Dec 2025 stood at $741000.0 (up 36.97% YoY), and the FY2025 full-year result was $741000.0, up 36.97% from the prior year.
- Amortization of Deferred Charges grew to $193000.0 in Q4 2025, from $188000.0 in the prior quarter.
- In the past five years, Amortization of Deferred Charges ranged from a high of $637000.0 in Q2 2023 to a low of $57000.0 in Q3 2023.
- A 5-year average of $339200.0 and a median of $341000.0 in 2021 frame the typical range for Amortization of Deferred Charges.
- Across the five-year window, Amortization of Deferred Charges slumped 89.77% in 2023 and soared 217.54% in 2024, its largest moves.
- Tracing CORT's Amortization of Deferred Charges over 5 years: stood at $508000.0 in 2021, then rose by 11.02% to $564000.0 in 2022, then tumbled by 89.72% to $58000.0 in 2023, then soared by 208.62% to $179000.0 in 2024, then gained by 7.82% to $193000.0 in 2025.
- Business Quant data shows CORT's Amortization of Deferred Charges at $193000.0 in Q4 2025, $188000.0 in Q3 2025, and $183000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Corcept Therapeutics | 10.09 Bn | 9.76 Bn | 162.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 193,000.00 |
| Dec 31, 2025 | 193,000.00 |
| Sep 30, 2025 | 188,000.00 |
| Sep 30, 2025 | 188,000.00 |
| Jun 30, 2025 | 183,000.00 |
| Jun 30, 2025 | 183,000.00 |
| Mar 31, 2025 | 177,000.00 |
| Mar 31, 2025 | 177,000.00 |
| Dec 31, 2024 | 179,000.00 |
| Dec 31, 2024 | 179,000.00 |
| Sep 30, 2024 | 181,000.00 |
| Sep 30, 2024 | 181,000.00 |
| Jun 30, 2024 | 122,000.00 |
| Jun 30, 2024 | 122,000.00 |
| Mar 31, 2024 | 59,000.00 |
| Mar 31, 2024 | 59,000.00 |
| Dec 31, 2023 | 58,000.00 |
| Dec 31, 2023 | 58,000.00 |
| Sep 30, 2023 | 57,000.00 |
| Sep 30, 2023 | 57,000.00 |